A real-world study on hospital and economic burden of dengue fever in French overseas territories.

Julie Cornebise¹, Solenne Tauty², Anouar Salhi², Cédric Strub¹, Franck Favre-Besse¹, Françoise Bugnard², Cinira Lefèvre³, Samuel Markowicz⁴

¹Takeda France, Paris, France.

²Stève consultants, a Cytel company, Oullins-Pierre-Bénite, France.

³Takeda France, Paris, France. Electronic address: cinira.lefevre@takeda.com.

⁴Department of Infectious and Tropical Diseases, University Hospital Center of Point-a-Pitre, Guadeloupe, France.

PubMed DOI

Abstract

INTRODUCTION: Dengue incidence significantly increased in recent years, representing a public health threat in French overseas territories. Real-world data on its burden is lacking by territory/age groups. OBJECTIVES: To describe the hospital burden and associated costs of dengue in French overseas territories. METHODS: Using the French national hospital database (PMSI), dengue hospitalizations…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.